Static Image
TAKE CARE: Advocacy Blog Series

TAKE CARE: Advocacy Blog Series

Update on the Affordable Care Act We are continuing our advocacy blog series meant to help you take care when it comes to important arthritis health care and coverage issues. If you are just now tuning into this series, check out our previous blog posts on accumulator adjustment programs, pharmacist gag orders, President Trump’s drug pricing blueprint, drug rebates, and premium increases. This week, we break down a recent legal challenge to the Affordable Care Act (ACA). A court case was recently thrown into the spotlight as a result of the administration’s decision to file a brief essentially arguing that federal courts ...more
More Weight Loss Is Better for Knee OA

More Weight Loss Is Better for Knee OA

When it comes to easing the symptoms of knee osteoarthritis (OA), the more weight loss, the better, according to researchers at Wake Forest University in Winston-Salem, North Carolina. In a study published recently online in Arthritis Care & Research, Stephen Messier, PhD, and colleagues report that overweight and obese adults aged 55 and older with knee OA who lost 20 percent or more of their body weight saw far greater improvements in pain, function, quality of life, inflammation and knee joint stress than those who lost less. In an earlier trial, the same researchers found that a weight loss of 10 ...more
Strength Comes in Numbers This Juvenile Arthritis Awareness Month

Strength Comes in Numbers This Juvenile Arthritis Awareness Month

On June 28th, friends and families from all over the United States flocked to Bellevue, Washington, to connect, play and learn at the 2018 National Juvenile Arthritis Conference. With a turnout of over 1,000 people, the event began with a bang and was a massive success! Now that the Conference has wound down, it is officially July, which is Juvenile Arthritis Awareness Month! And the Arthritis Foundation wants YOU to join the fight! JA: Our Heroes’ Nemesis Every day, 300,000 kids nationwide fight against this disease. There are many types of juvenile arthritis, as well as its henchmen: other childhood rheumatic conditions such as ...more
Calling All Superheroes! The 2018 National Juvenile Arthritis Conference Begins Today!

Calling All Superheroes! The 2018 National Juvenile Arthritis Conference Begins Today!

Today, approximately 1,000 superheroes – kids, teens, young adults and their families – from across the country, have answered the call and have made their way to Bellevue, Washington. Bellevue – a city located across Lake Washington from Seattle – is the first location of the Arthritis Foundation’s signature National Juvenile Arthritis (JA) Conference. The JA Conference is a unique opportunity to connect families, kids, teens and young adults affected by JA and other rheumatic diseases who spend the weekend networking, learning, sharing tips and forming connections that can last a lifetime. Held at the Hyatt Regency Bellevue on Seattle’s Eastside, a property ...more
Biosimilar Substitution Victories Across the Country!

Biosimilar Substitution Victories Across the Country!

The Arthritis Foundation thanks the governors in eight states for signing biosimilar legislation in 2018 that enhances patient access to new and innovative medications, while ensuring that pharmacists are communicating critical, up-to-date medical information about patients to physicians. New laws in Connecticut, Michigan, New Hampshire, South Dakota, Vermont, Wyoming, West Virginia and Wisconsin will positively impact approximately 5.3 million people with doctor-diagnosed arthritis. “This legislation will grant access to life-changing medications while ensuring proper safeguards for both patient and physician when a prescription is substituted,” said Connecticut Advocacy Chair Paula Haney. In Wyoming, Sen. Fred Baldwin (bill sponsor) said: “The passage of ...more
FDA Approves a New Oral Drug for Moderate to Severe RA

FDA Approves a New Oral Drug for Moderate to Severe RA

People with moderate to severe rheumatoid arthritis (RA) who haven’t responded well to one or more tumor necrosis factor (TNF) inhibitor medications now have a new option. The U.S. Food and Drug Administration (FDA) recently approved baricitinib (Olumiant), a pill that is taken once a day. Baricitinib is a targeted disease-modifying antirheumatic drug (DMARD) that blocks Janus kinase (JAK), a group of enzymes that enable inflammatory signals to be activated inside a cell. It’s the second in this class of drug to hit the market for the treatment of RA; tofacitinib (Xeljanz) was the first, approved in 2012. “It’s not a biologic ...more
Every Catch Deserves a Touchdown Dance

Every Catch Deserves a Touchdown Dance

Charcandrick West, professional football player with Louisiana roots, gets real about what keeps him going, how no hurdle is too high and why he likes to win on and off the field. Q1: When did you realize you wanted to play football professionally? I don’t remember the first moment I grasped a football, but the second I did, probably around age 6, I was hooked. I still remember being a kid, looking up from the field and seeing my mom and dad cheer me on. It was a thrill to know I was making people in the stands happy by giving the ...more
TAKE CARE: Advocacy Blog Series

TAKE CARE: Advocacy Blog Series

Premium Increases We’re excited to continue our advocacy blog series meant to help you take care when it comes to important arthritis health care and coverage issues. If you are just now tuning into this series, check out our previous blog posts on accumulator adjustment programs, pharmacist gag orders, President Trump’s drug pricing blueprint and drug rebates. This week we are focusing on the rise in premiums for health plans sold on the Affordable Care Act exchanges. Read on to learn more about how these increases may or may not impact your health insurance options. How do I know if I will be ...more
RA Research Briefs: Tofacitinib, Fish, Remission

RA Research Briefs: Tofacitinib, Fish, Remission

Keep up-to-date on the latest rheumatoid arthritis (RA) research with our brief research summaries. Tofacitinib Plus Methotrexate May Work As Well As Biologic If methotrexate (MTX) alone fails to control RA, adding the oral Janus kinase (JAX) inhibitor tofacitinib (Xeljanz) may be as effective as the standard practice of adding a biologic. The JAX inhibitor belongs to the third category of disease-modifying antirheumatic drugs (DMARDs) called targeted DMARDs. In a study of 1,146 patients with rheumatoid arthritis that had not adequately responded to MTX alone, approximately a third were switched to tofacitinib, while the others received either tofacitinib or the biologic adalimumab ...more
Study Ranks Treatments for Knee OA

Study Ranks Treatments for Knee OA

A new study takes a look at which approaches are best to bring relief to people with knee osteoarthritis (OA), a condition that affects approximately 20 percent of people over the age of 45 in the United States. Knee OA can be extremely painful and limit a person’s ability to function. Although there is no cure, numerous treatments are available to reduce symptoms, including over-the-counter and prescription drugs. Exercising and losing weight if a patient is overweight or obese also can help. Total knee replacement surgery is effective but is done only in cases where the disease is advanced and it’s ...more